Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
View Patent ↗In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.
1. An isolated antibody that binds to a polypeptide consisting of the amino acids identified in SEQ ID NO.1 as 236-239, an antigen-binding fragment of said antibody, or an antigen-binding derivative comprising all of the complementarity determining regions of said antibody.
2. An isolated antibody, an antigen-binding fragment of said antibody, or an antigen-binding derivative comprising all of the complementarity determining regions of said antibody, that competes with a second antibody for binding to cMet hepatocyte growth factor receptor (Met) at amino acids 236-239 of SEQ. ID No. 1, wherein said second antibody is a monoclonal antibody produced by hybridoma cell line Accession Number PTA-7680 deposited in the American Type Culture Collection.
3. The isolated antibody, antigen-binding fragment, or antigen-binding derivative of claim 2 , which is the antigen-binding derivative of said antibody.
4. A composition comprising the antibody, fragment, or derivative of claim 2 .
5. The composition of claim 4 , further comprising a carrier.
6. The composition of claim 5 wherein the antibody, fragment, or derivative is linked to a detectable moiety.
7. The composition of claim 4 wherein the antibody, fragment, or derivative is linked to a detectable moiety.
8. A method for detecting a presence of Met in a tissue or a biological sample, which tissue or biological sample is suspected of expressing Met, comprising the steps of: (a) providing the tissue or biological sample suspected of expressing Met; (b) providing the composition of claim 7 ; (c) contacting the tissue or biological sample with the composition of claim 7 wherein the isolated antibody, antigen-binding fragment, or antigen-binding derivative of the composition binds to any Met in the tissue or biological sample, and (d) detecting the detectable moeity in any said bound isolated antibody, antigen-binding fragment, or antigen-binding derivative to determine the presence of Met in the tissue or biological sample.
9. The method of claim 8 wherein the tissue or biological sample has been fixed in a solution of formaldehyde.
10. A method of diagnosing or prognosing a cancer associated with Met expression or translocation in a patient having or suspected of having a cancer associated with Met expression or translocation, comprising the steps of: (a) obtaining a tissue or a biological sample from said patient; (b) providing the composition of claim 7 ; (c) contacting the tissue or biological sample with the composition of claim 7 , wherein the isolated antibody, antigen-binding fragment, or antigen-binding derivative of the composition binds to any Met in the tissue or biological sample; (d) detecting the detectable moeity in any said bound isolated antibody, antigen-binding fragment, or antigen-binding derivative to determine an expression level of Met in the tissue or biological sample; and (e) comparing the expression level to a control, wherein an altered expression level indicates a cancer associated with Met expression or translocation in the patient.
11. The method of claim 10 wherein the tissue or biological sample has been fixed in a solution of formaldehyde.
12. The method of claim 10 wherein the cancer associated with Met expression or translocation is ovarian cancer.
13. A method for determining an effectiveness of a Met-inhibitory agent, comprising the steps: (a) obtaining a first tissue or biological sample from a patient having a cancer associated with Met expression or translocation; (b) treating the patient with a Met inhibitory agent; (c) obtaining a post-treatment tissue or biological sample from the patient; (d) providing the composition of claim 7 ; (e) contacting each of the first tissue or biological sample and the post-treatment tissue or biological sample with the composition of claim 7 , wherein the isolated antibody, antigen-binding fragment, or antigen-binding derivative of the composition binds to any Met in each of the first tissue or biological sample and the post-treatment tissue or biological sample; (f) detecting the detectable moeity in any said bound isolated antibody, antigen-binding fragment, or antigen-binding derivative in each of the first tissue or biological sample and the post-treatment tissue or biological sample to determine an expression level of Met in the first tissue or biological sample and an expression level of Met in the post-treatment tissue or biological sample; and (g) comparing the Met expression level of the first tissue or biological sample with the Met expression level of the post-treatment tissue or biological sample to determine the effectiveness of said Met-inhibitory agent.
14. The method of claim 13 wherein each of the first tissue or biological sample and the post-treatment tissue or biological sample has been fixed in a solution of formaldehyde.
15. A kit, comprising: (a) a first container comprising the isolated antibody, fragment or derivative of claim 2 ; (b) a second container comprising a carrier and (c) instructions for using the isolated antibody to detect Met, diagnose, prognose, or evaluate a Met inhibitory agent.
16. The kit of claim 15 wherein the isolated antibody, fragment, or derivative is linked to a detectable moiety.
17. The kit of claim 15 further including a third antibody or antigen-binding fragment thereof; which third antibody or fragment thereof binds to the isolated antibody, fragment, or derivative from the first container.
18. The kit of claim 17 wherein the third antibody is labeled with a detectable moiety.
19. The kit of claim 15 further including a Met-inhibitory agent.
20. An isolated antibody that binds to a polypeptide consisting of the amino acids identified in SEQ ID NO. 1 as 236-242, an antigen-binding fragment of said antibody, or an antigen-binding derivative comprising all of the complementarily determining regions of said antibody.
21. The isolated antibody or antigen-binding fragment of claim 20 , which is a polyclonal antibody.